Connect with us

Politics

Bill To Legalize Hemp Passes Key Senate Committee

Published

on

A wide-ranging agricultural bill that includes a provision to legalize hemp made its way through a crucial Senate committee on Wednesday, passing 20-1.

Last week, Senate Majority Leader Mitch McConnell (R-KY) inserted the cannabis provisions—which would remove hemp from the federal definition of marijuana and also free up hemp cultivators to receive federal crop insurance—into the 2018 Farm Bill. The move builds upon the senator’s successful effort to include protections for industrial hemp research programs against federal interference in the 2014 version of the bill.

“I think it’s time we took this step,” McConnell said before the Senate Committee on Agriculture, Nutrition and Forestry on Wednesday. “I think everybody has now figured it out that this is not the other plant,” he added, referring to hemp’s cannabis cousin, marijuana.

“All the people in rural Kentucky who grew up with tobacco are hoping that this will be really something. And as we all know, hemp is very diversified. It can end up in your car dashboard, it can end up in food, it can end up in certain kinds of pharmaceuticals. It’s time to figure it out and see where the market will take us. I think it’s an important new development in American agriculture.”

McConnell also appeared on the Senate floor earlier Wednesday to reaffirm his support for the bill’s hemp provision.

“It’s a landmark piece of legislation that will benefit farmers and communities throughout our country,” McConnell said. “I’m particularly excited that the legislation being considered today includes provisions from the Hemp Farming Act of 2018…which I introduced earlier this year.”

“This will empower farmers in Kentucky and other states to fully realize the potential of industrial hemp.”

Late on Tuesday, Sen. Chuck Grassley (R-IA) filed an amendment to the Farm Bill that would require the Justice Department to “modify the definition of the term ‘hemp’ and make a determination as to whether cannabidiol [CBD] should be a controlled substance” under federal law.

Hemp legalization advocates swiftly responded, urging committee members to oppose the proposed changes, which they feared would gut the intent of McConnell’s legislation.

Kentucky’s Commissioner of Agriculture also tweeted that “I STRONGLY oppose Senator Grassley’s Amendment.”

Grassley spoke in defense of his proposed amendment, lamenting that he’d “objected on procedural grounds” to the hemp legalization provision and was ignored. He also argued that he’d support the legalization of industrial hemp, but not its derivatives such as CBD. Grassley voiced concerns that the bill would “allow any snake oil salesman” to peddle unregulated CBD products to patients suffering from conditions such as epilepsy and anxiety.

Grassley also claimed that the hemp legalization provision falls “squarely within the Judiciary Committee’s jurisdiction,” which he chairs, as opposed to the Senate Committee On Agriculture.

Notably, however, he didn’t call for a committee vote on his proposed amendment. Instead, he asked that members “work with me to modify this provision after this bill gets out of committee.”

McConnell pushed back against the senator’s remarks. He said that he felt confident in the integrity of the bill and the safeguards it provides after consulting with the Justice Department, the Food and Drug Administration (FDA) and the ranking member of the Senate Committee on the Judiciary. Grassley’s amendment would “undercut essential premise of the bill, namely that help and its derivatives should be a legal agricultural commodity,” McConnell said.

“Hemp should be allowed to flourish again in this county…”

During the Wednesday committee markup, several lawmakers voiced support for legalizing hemp, including Sens. Michael Bennet, (D-CO), Heidi Heitkamp (D-ND) and Amy Klobuchar (D-MN).

Though the bill could still be subject to further amendments when it reaches the Senate floor, it’s doubtful that the hemp provisions would face significant resistance given their sizable bipartisan support. McConnell is joined by Senate Minority Leader Chuck Schumer (D-NY) and Sen. Ron Wyden (D-OR), among others, who also favor of the provision.

McConnell also said he received assurances from U.S. Attorney General Jeff Sessions, a staunch marijuana prohibitionist, that while he wouldn’t embrace the hemp legalization move, he “is not going to oppose us,” the Associated Press reported.

Lawmakers argue that federal laws pertaining to hemp cultivation have done a disservice to farmers and businesses in the United States. While it’s legal to sell hemp products, such as clothing and cosmetics, it remains illegal to cultivate the non-psychoactive cousin of marijuana under federal law.

Wyden took to the Senate floor last week, accompanied by two baskets full of hemp products, to make just that point.

“There can’t be many policies on the books that are more anti-farmer than that one,” he said. “Hemp growers in places like Canada and China must just be laughing all the way to the bank. They’re cashing in, while our farmers have their hands tied by the current hemp restrictions.”

And in a statement provided to Marijuana Moment on Wednesday, Wyden said that [l]ifting the nonsensical ban on growing hemp in Oregon and nationwide reverses decades of policymaking that hurt farmers’ ability to innovate and grow jobs here at home.”

“Our bipartisan legislation will help farmers unlock the full economic potential of industrial hemp, spurring economic growth and creating good-paying red, white, and blue jobs in rural communities across the country. Passing the Hemp Farming Act through the Senate Agriculture Committee marks a huge step toward allowing consumers to buy products made with hemp grown in America.”

“It’s a crock,” Schumer, the Democratic leader, said last month, of the nation’s ban on hemp. “It makes no sense that the [Drug Enforcement Administration] is the primary regulator, and that they stop farmers and investors from growing hemp. Why are we buying hemp from other countries, when we have hundreds of acres that could be grown right here in our backyard?”

In a related move, for the third year in a row, the Senate unanimously adopted a resolution last week that acknowledged “the growing economic potential of industrial hemp.” But with the 2018 Farm Bill, this could represent the first year that a hemp legalization provision actually passes in the Senate.

All of this hemp momentum comes as many lawmakers are vying for broader cannabis reform measures, including the newly filed STATES Act, which would exempt marijuana from the Controlled Substances Act for states where the plant has been legalized. It would also provide protections for banks dealing with legal cannabis businesses and legalize industrial hemp.

President Donald Trump told reporters that he “probably will end up supporting that [bill],” last week.

Attempts to include hemp-related amendments to the House version of the Farm Bill were blocked last month. That said, the Senate leader is in a good position to push the legislation forward through a bicameral conference committee, which will eventually craft a final bill to send to the president’s desk.

McConnell said a full Senate vote on the bill would take place before July 4.

See below for a summary of the Farm Bill’s hemp provisions, as prepared by the Agriculture Committee:

Sec. 7125 Supplemental and Alternative Crops; Hemp
x Reauthorizes a research project for supplemental and alternative crops including canola and hemp.

Sec. 7401 Critical Agricultural Materials Act
x Reauthorizes the Critical Agricultural Materials Act, and includes hemp as an eligible product.

Sec. 7415 Legitimacy of Industrial Hemp Research
x Requires the Secretary to conduct a study and report on the economic viability of the domestic production and sale of industrial hemp.

Sec. 10111 Hemp Production
x Amends the Agricultural Marketing Act of 1946 to allow states to regulate hemp growth and production, based on a state or tribal plan that includes information on locations of hemp production, testing for THC concentration, disposal of plants that are out of compliance, and negligence or other violations of the state or tribal plan.
x Requires states and tribes without USDA approved plans to follow federal laws and regulations promulgated by USDA on hemp production.

Sec. 10112 Rule of Construction
x Clarifies that nothing in this title authorizes interference with the interstate commerce of hemp.

Sec. 11101 Definitions
x Defines cover crop termination and defines hemp as used in section 297A of the Agricultural Marketing Act of 1946.

Sec. 11106 Insurance period
x Amends section 508(a)(2) of the Federal Crop Insurance Act by adding hemp.

Sec. 11112 Submission of policies and materials to board.
x Amends section 508(h) of the Federal Crop Insurance Act to allow the Corporation to waive the viability and marketability requirement in the case of a policy or pilot program relating to the production of hemp.

Sec. 11120 Agricultural commodity
x Amends section 518 of the Federal Crop Insurance Act by adding hemp.

Sec. 11121 Reimbursement of research, development, and maintenance costs
x Amends section 522(b) of the Federal Crop Insurance Act to allow the Board and Corporation to waive the viability and marketability requirements in the case of research and development relating to a policy to insure the production of hemp.

UPDATE June 13, 2018 8:38am PT: This story has been updated to include new comments from Sens. Grassley and McConnell.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Kyle Jaeger is Marijuana Moment's Sacramento-based senior editor. His work has also appeared in High Times, VICE and attn.

Politics

Colorado Activists File Revised Ballot Initiatives To Legalize Psilocybin And Establish ‘Healing Centers’

Published

on

Colorado activists have filed revised versions of a pair of 2022 ballot initiatives to legalize psilocybin and create licensed “healing centers” where people can use the psychedelic for therapeutic purposes. The move comes as state lawmakers have introduced a separate bill to require a study into the efficacy of plant-based psychedelics.

The ballot measures—filed by Kevin Matthews, the campaign manager behind Denver’s historic 2019 vote to locally decriminalize psilocybin and entrepreneur Veronica Perez—are similar to earlier versions the advocates filed with the secretary of state’s office last month, with a few key changes concerning the rollout of the reform, promoting equity and possession limits.

For the original initiatives, the campaign was considering two options: one would have legalized a wide range of entheogenic substances including DMT, ibogaine and mescaline, as well as establish a regulatory model for psychedelics therapy. The other would have initially enacted the reform for psilocybin and psilocin alone.

But recognizing that regulators would be faced with an onerous task to set up rules for multiple psychedelics, activists decided to take a different approach with the new measures. For both, there would be a two-tiered regulatory model, where only psilocybin would be legalized and regulated for therapeutic use until June 2026, after which point regulators could expand the policy change to include other psychedelics that are listed in the proposal.

“We really wanted to make sure that the administration had time to set up a proper regulatory structure—first for psilocybin and then for any further natural medicines,” Rick Ridder of RBI Strategies, a spokesperson for the campaign, told Marijuana Moment on Monday.

The decision to add additional psychedelics to the program would be made by the Department of Regulatory Agencies in consultation with a Natural Medicine Advisory Board that would be established. The board would be comprised of 15 members, including people who have experience with psychedelic medicine in a scientific and religious context.

Another major change from the prior versions is that the revised initiatives do not contain explicit “allowable” possession limits—a provision that had garnered pushback from certain Colorado activists when the original measures were filed.

And unlike the last two versions of the initiatives, these new measures also include specific provisions meant to “ensure the regulatory access program is equitable and inclusive and to promote the licensing of and the provision of natural medicine services” for people who have been disproportionately impacted by drug criminalization, who face challenges accessing health care, have “traditional or indigenous history with natural medicines” and military veterans.

Those rules could involve, but are not limited to, reduced licensing fees, reduced costs for low-income people and an annual review of “the effectiveness of such policies and programs.”

“I think what this is is a giant step forward for mental health treatment in the state of Colorado,” Ridder said. “As we’ve looked at the results of research throughout the world, we’re seeing very promising data related to particularly healthy people with PTSD, with suicidal tendencies and end-of-life. And this is just an opportunity to bring that kind of natural medicine and medicinal help to citizens here in Colorado.”

The two new initiatives are nearly identical to each other, except that one contains a component specifically authorizing people to petition courts for record sealing for past convictions that would be made legal under the proposal.

Under the proposals, the Department of Regulatory Agencies would be responsible for developing rules for a therapeutic psychedelics program where adults 21 and older could visit a licensed “healing center” to receive treatment under the guidance of a trained facilitator.

This latest filing comes more than two years after Denver became the first city in the U.S. to decriminalize psilocybin mushrooms. Various activists, including those involved in the 2019 campaign, have signaled interest in building upon the reform.

The initiatives must still be assigned an official ballot title and summary from the state before they’re approved to begin signature gathering. The measures are scheduled to receive a review and comment hearing on February 3. If approved by state officials, activists will choose one of the measures to pursue and will then need to collect 124,632 valid signatures from registered voters to achieve ballot access.

The Colorado ballot initiatives seek to accomplish something similar to what California activists are actively pursuing. California advocates are in the process of collecting signatures for a ballot initiative to legalize psilocybin mushrooms in the state.

Meanwhile, in Colorado, Sen. Joann Ginal (D) and Rep. Alex Valdez (D) filed a modest bill last week to create a one-year plant-based medicine policy review panel that would be tasked with studying the “use of plant-based medicines to support mental health,” according to a summary. The ballot campaign is not affiliated with that legislative effort.


Marijuana Moment is already tracking more than 1,000 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.

Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.

“The policy review panel shall submit a report on its findings and policy recommendations to the House of Representatives Public and Behavioral Health and Human Services Committee and the Senate Health and Human Services Committee, or any successor committees; the governor; and the Department of Human Services,” it says.

Meanwhile, legislative efforts to enact psychedelics reform are also underway in other states across the country.

For example, a bill to decriminalize a wide array of psychedelics in Virginia was taken up by a House of Delegates panel on Monday, only to be pushed off until 2023. But there’s still a separate but similar reform proposal that’s pending in the Senate.

Two Republican Oklahoma lawmakers recently filed bills meant to promote research into the therapeutic potential of psilocybin, and one of the measures would further decriminalize low-level possession of the psychedelic.

A GOP Utah lawmaker also introduced a bill last week that would set up a task force to study and make recommendations on the therapeutic potential of psychedelic drugs and possible regulations for their lawful use.

In Kansas, A lawmaker also recently filed a bill to legalize the low-level possession and cultivation of psilocybin mushrooms.

A Republican Missouri lawmaker introduced a bill this month to give residents with serious illnesses legal access to a range of psychedelic drugs like psilocybin, ibogaine and LSD  through an expanded version of the state’s existing right-to-try law.

California Sen. Scott Wiener (D) told Marijuana Moment in a recent interview that his bill to legalize psychedelics possession stands a 50/50 chance of reaching the governor’s desk this year. It already cleared the full Senate and two Assembly committees during the first half of the two-year session.

In Michigan, a pair of state senators introduced a bill in September to legalize the possession, cultivation and delivery of various plant- and fungi-derived psychedelics like psilocybin and mescaline.

Washington State lawmakers also introduced legislation this month that would legalize what the bill calls “supported psilocybin experiences” by adults 21 and older.

In Vermont, a broad coalition of lawmakers representing nearly a third of the House introduced a bill to decriminalize drug possession.

New Hampshire lawmakers filed measures to decriminalize psilocybin and all drugs.

Last year, the governor of Connecticut signed legislation that includes language requiring the state to carry out a study into the therapeutic potential of psilocybin mushrooms.

At the congressional level, bipartisan lawmakers sent a letter to the Drug Enforcement Administration (DEA) this month, urging that the agency allow terminally ill patients to use psilocybin as an investigational treatment without the fear of federal prosecution.

Virginia House Committee Pushes Back Psychedelics Decriminalization Bill Until 2023, But Senate Proposal Still Pending

Photo courtesy of Dick Culbert.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Business

Amazon Endorses GOP-Led Bill To Federally Legalize Marijuana

Published

on

Amazon, the second largest private employer in the U.S., is backing a Republican-led bill to federally legalize, tax and regulate marijuana.

The company’s public policy division said on Tuesday that it is “pleased to endorse” the legislation from Rep. Nancy Mace (R-SC), who filed the States Reform Act in November as a middle-ground alternative to more scaled back GOP proposals and wide-ranging legalization bills that are being championed by Democrats.

“Like so many in this country, we believe it’s time to reform the nation’s cannabis policy and Amazon is committed to helping lead the effort,” the company, which previously expressed support for a separate, Democratic-led legalization bill, said.

Amazon has worked to adapt to changing marijuana policies internally as it’s backed congressional reform, enacting an employment policy change last year to end drug testing for cannabis for most workers, for example.

Months after making that change—and following the introduction of the States Reform Act—Mace met with Amazon and received the company’s endorsement, Forbes reported.

“They don’t want to sell it,” the freshman congresswoman said, adding that Amazon is primarily interested in backing the reform for hiring purposes instead of as a way to eventually sell cannabis. “It opens up the hiring pool by about 10 percent.”

Brian Huseman, Amazon’s vice president of public policy, said the bill “offers comprehensive reform that speaks to the emergence of a bipartisan consensus to end the federal prohibition of cannabis.”

Amazon’s drug testing decision was widely celebrated by reform advocates and industry stakeholders. Initially, the company only talked about ending the policy going forward. But it later disclosed that the policy change would also be retroactive, meaning former workers and applicants who were punished for testing positive for THC will have their employment eligibility restored.

The reason for the move away from marijuana testing was multifaceted, Amazon said at the time. The growing state-level legalization movement has made it “difficult to implement an equitable, consistent, and national pre-employment marijuana testing program,” data shows that drug testing “disproportionately impacts people of color and acts as a barrier to employment” and ending the requirement will widen the company’s applicant pool.

The GOP congresswoman’s bill already has the support of the influential, Koch-backed conservative group Americans for Prosperity.

The measure would end federal cannabis prohibition while taking specific steps to ensure that businesses in existing state markets can continue to operate unencumbered by changing federal rules.

Mace’s legislation has been characterized as an attempt to bridge a partisan divide on federal cannabis policy. It does that by incorporating certain equity provisions such as expungements for people with non-violent cannabis convictions and imposing an excise tax, revenue from which would support community reinvestment, law enforcement and Small Business Administration (SBA) activities.

Marijuana Moment first reported on an earlier draft version of the bill in November, and it quickly became apparent that industry stakeholders see an opportunity in the Republican-led effort.

The reason for that response largely comes down to the fact that there’s skepticism that Democratic-led legalization bills—including the Marijuana Opportunity, Reinvestment and Expungement (MORE) Act that Amazon has also endorsed—will be able to pass without GOP buy-in. While Democrats hold majorities in both chambers, in addition to controlling the White House, the margins for passage are slim.

The MORE Act did clear the House Judiciary Committee in September, and a previous version passed the full House during the last Congress. Senate leadership is preparing to file a separate legalization proposal after unveiling a draft version in July.

Virginia House Committee Pushes Back Psychedelics Decriminalization Bill Until 2023, But Senate Proposal Still Pending

Photo courtesy of Max Pixel.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

Virginia House Committee Pushes Back Psychedelics Decriminalization Bill Until 2023, But Senate Proposal Still Pending

Published

on

A bill to decriminalize a wide array of psychedelics in Virginia was taken up by a House of Delegates panel on Monday, only to be pushed off until 2023. But there’s still a separate but similar reform proposal that’s pending in the Senate.

Advocates were hopeful that a House Courts of Justice subcommittee would advance the reform, especially after an amendment from the sponsor was adopted to more narrowly apply decriminalization to medical practitioners and people using psychedelics in treatment with a practitioner.

But following some discussion of Del. Dawn Adams’s (D) bill, members approved a motion to carry it over to next year to give the legislature more time to refine it and build support. It was a disappointment for activists, and there was particular surprise that the delay motion was made by House Minority Leader Charniele Herring (D)‎, who is well known for championing marijuana legalization in the state.

Adams said in her opening remarks before the subcommittee that she has “spent considerable time hearing from researchers, meeting with both local and nationwide community advocates, speaking with veterans and personally reading dozens of publications and studies about the benefits of plant medicine.”

“What I’ve been able to learn is that there is strong evidence to support plant medicines—once thought dangerous—that really are effective and safe treatments,” she said.

There seemed to be some confusion among certain members about what the legislation would actually do.


Marijuana Moment is already tracking more than 1,000 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.

Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.

One member asked whether doctors would be able to prescribe psychedelics and whether the state would “see peyote stores and psilocybin stores basically popping up.”

The bill as amended wouldn’t legalize psychedelics for medical or recreational use. It would simply make it so practitioners and people participating in psychedelics treatment would face a $100 fine for possessing peyote, ibogaine, psilocybin or psilocyn. Currently, such possession is considered a Class 5 felony.

Any dollars collected from psychedelics possession violations would go to the state’s Drug Offender Assessment and Treatment Fund, which supports substance misuse treatment programs and drug courts.

But following testimony from advocates and researchers, Herring said that “there’s a lot of issues have been raised” and that she’d like to see a “prescription element” built into the legislation. Of course, because the psychedelics are federally controlled substances, doctors are precluded from prescribing them, but they could theoretically make recommendations, as is done in medical cannabis states.

In any case, the motion carried and that bill has now been set aside until next year. Now advocates are eager to see what happens with a separate, more limited reform measure that was considered in the Senate Judiciary Committee last week.

At that meeting, there was bipartisan support—including from the GOP minority leader—but also talk about making the decriminalization proposal more medically focused. The sponsor, Sen. Ghazala Hashmi (D), agreed to go back and make revisions so that the panel could reconsider it at a future meeting. The expectation was that it would be taken back up this week, but it’s not currently listed on the panel’s agenda for Wednesday.

The bill is scaled back compared to the House version because, as drafted, it would only decriminalize psilocybin and psilocyn by adults 21 and older. It’s unclear what kind of amendments the sponsor might offer when the committee takes up the legislation again.

At a recent virtual event organized by the reform group Decriminalize Nature Virginia, the sponsors of both bills participated as hosts, sharing their perspectives about the growing body of research indicating that psychedelics could be powerful tools to combat conditions like treatment-resistant depression and post-traumatic stress disorder (PTSD).

If the legislature does approve the legislation, it could face resistance from the state’s incoming Republican governor, Glenn Youngkin, who has expressed concerns about implementing a commercial marijuana market in line with what the Democratic legislature and outgoing governor approved last year.

These psychedelics reform proposals are some of the latest to be introduced in state legislatures this session as the decriminalization movement spreads.

For example, two Republican Oklahoma lawmakers recently filed bills meant to promote research into the therapeutic potential of psilocybin, and one of the measures would further decriminalize low-level possession of the psychedelic.

A GOP Utah lawmaker also introduced a bill last week that would set up a task force to study and make recommendations on the therapeutic potential of psychedelic drugs and possible regulations for their lawful use.

In Kansas, A lawmaker also recently filed a bill to legalize the low-level possession and cultivation of psilocybin mushrooms.

A Republican Missouri lawmaker introduced a bill this month to give residents with serious illnesses legal access to a range of psychedelic drugs like psilocybin, ibogaine and LSD  through an expanded version of the state’s existing right-to-try law.

California Sen. Scott Wiener (D) told Marijuana Moment in a recent interview that his bill to legalize psychedelics possession stands a 50/50 chance of reaching the governor’s desk this year. It already cleared the full Senate and two Assembly committees during the first half of the two-year session.

In Michigan, a pair of state senators introduced a bill in September to legalize the possession, cultivation and delivery of various plant- and fungi-derived psychedelics like psilocybin and mescaline.

Washington State lawmakers also introduced legislation this month that would legalize what the bill calls “supported psilocybin experiences” by adults 21 and older.

In Vermont, a broad coalition of lawmakers representing nearly a third of the House introduced a bill to decriminalize drug possession.

New Hampshire lawmakers filed measures to decriminalize psilocybin and all drugs.

Last year, the governor of Connecticut signed legislation that includes language requiring the state to carry out a study into the therapeutic potential of psilocybin mushrooms.

At the congressional level, bipartisan lawmakers sent a letter to the Drug Enforcement Administration (DEA) this month, urging that the agency allow terminally ill patients to use psilocybin as an investigational treatment without the fear of federal prosecution.

Oklahoma Republicans File Bills To Decriminalize Psilocybin And Encourage Research On Medical Benefits

Photo elements courtesy of carlosemmaskype and Apollo.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading
Advertisement

Marijuana News In Your Inbox

Support Marijuana Moment

Marijuana News In Your Inbox

Marijuana Moment